CD4 and HIV infectious disease: Subsequently, the use of bNAb-based vaccines in human trials has generated tremendous interest and clinical trials such as the Antibody Mediated Prevention (AMP) studies (HVTN 703/HPTN 081 and HVTN 704/HPTN 085) are being conducted to test whether VRC01, a potent bNAb designed to target the CD4+ binding site of the HIV-1 envelope glycoprotein, can prevent HIV infection in men who have sex with men as well as heterosexual women (106).